Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms

Launched by PEKING UNIVERSITY · Sep 16, 2017

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. sign written informed consent form
• • 2. age ≥ 18 years
• • 3. pathologically confirmed neuroendocrine, Ki67\>=10%;
• • 4. ECOG 0-1;
• • 5. No prior antitumor treatment with chemotherapy targeting regimens for neuroendocrine carcimomas, no more than 2 systematic treatment for neuroendocrine tumors;
• • 6. Unresectable disease;
• • 7. At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan \>=20mm, spiral CT scan \>=10mm, no prior radiation to measurable lesions);
• • 8. Predicted survival \>=3 months;
• • 9. Negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women;
• • 10. Sexually active males or females willing to practice contraception during the study until 30 days after end of study.
• Exclusion Criteria:
• • 1. In the process of antitumor therapy with effective response;
• • 2. Refuse to accept PET/CT;
• • 3. Pregnant or nursing, or sexually active males or females refuse to practice contraception during the study until 30 days after end of study;
• • 4. Person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons；